Next-gen therapeutics to spare and expand beta-cell mass. (December 2021)

• Record Type: Journal Article
• Authors: Bolla, Andrea Mario; Usuelli, Vera; Ben Nasr, Moufida; Frigerio, Sofia; Loretelli, Cristian; D'Addio, Francesca; Fiorina, Paolo
• Is Part Of: Current opinion in pharmacology. Volume 61(2021)
• Page Start: 77
• Page End: 82
• Publication Date: 2021-12
• Subjects: Pharmacology -- Periodicals; Pharmaceutical Preparations -- Periodicals; Drug Therapy -- Periodicals; Biopharmaceutics -- Periodicals; Pharmacologie -- Périodiques; Pharmacology; Periodicals; 615.105
• DOI: 10.1016/j.coph.2021.09.001
• Languages: English
• ISSNs: 1471-4892

Abstract

Abstract: The most effective and physiological way to treat hyperglycemia is to restore beta-cell function and to rescue production of endogenous insulin. Increasing evidence suggests that both type 1 and type 2 diabetes are characterized by a significant defect in beta-cell mass, leading to the manifestation of the disease. Novel alternative approaches are needed to spare and expand beta-cell mass in patients with diabetes. This review sets out to describe the latest findings on how to restore the beta-cell mass and function in both forms of diabetes to modulate their progression.